<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079607</url>
  </required_header>
  <id_info>
    <org_study_id>ASARIP1M</org_study_id>
    <nct_id>NCT05079607</nct_id>
  </id_info>
  <brief_title>Human Skin Safety Testing of a Mitopure Topical Product Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Volunteers</brief_title>
  <acronym>GLOW-Safety</acronym>
  <official_title>A Modified Draize Repeat Insult Patch Test in a Shared Panel of 50/100 Healthy Volunteers, to Investigate the Irritation and Sensitization Potential of Test Articles Following Repeated Cutaneous Patch Applications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amazentis SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Princeton Research Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amazentis SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the irritation and sensitization potential of&#xD;
      multiple topically applied test articles (containing different concentrations of Mitopure),&#xD;
      in a shared panel of healthy volunteers by means of repeated cutaneous patch applications&#xD;
      under occlusion based on the modified Draize method&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin safety as assessed by the number of adverse events of skin irritation and sensitization during human repeat insult patch testing (HRIPT)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Irritation/Irritant</condition>
  <condition>Sensitisation</condition>
  <arm_group>
    <arm_group_label>Mitopure Topical Formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mitopure Topical Formula 1</intervention_name>
    <description>topical skin cream containing the low dose mitophagy activator Mitopure</description>
    <arm_group_label>Mitopure Topical Formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mitopure Topical Formula 2</intervention_name>
    <description>topical skin cream containing the high dose mitophagy activator Mitopure</description>
    <arm_group_label>Mitopure Topical Formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males or females,18 years of age or older.&#xD;
&#xD;
          -  Completed written informed consent.&#xD;
&#xD;
          -  Female subject agrees to use an acceptable method of birth control (e.g. abstinence,&#xD;
             condoms, hormonal birth control, IUD, tubal ligation, hysterectomy, bilateral&#xD;
             oophorectomy, hysterectomy, post-menopausal for at least one year or male partner&#xD;
             vasectomy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  A current skin disease of any type apart from mild facial acne (e.g. eczema,&#xD;
             psoriasis) or has tattoos or excessive hair at the patch sites that would interfere&#xD;
             with patching/skin evaluations.&#xD;
&#xD;
          -  Heavy alcohol consumption (i.e. more than 21 units per week or 8 units a day for men,&#xD;
             more than 14 units per week or 4 units a day for women).&#xD;
&#xD;
          -  Current use or history of repeated use of street drugs.&#xD;
&#xD;
          -  A febrile illness lasting more than 24 hours in the six days prior to first patch&#xD;
             application.&#xD;
&#xD;
          -  Significant past medical history of hepatic, renal, cardiac, pulmonary, digestive,&#xD;
             haematological, neurological, locomotor or psychiatric disease.&#xD;
&#xD;
          -  Currently taking asthma medication or antihistamines for hay fever.&#xD;
&#xD;
          -  A history of multiple drug hypersensitivity.&#xD;
&#xD;
          -  Concurrent medication likely to affect the response to the test articles or confuse&#xD;
             the results of the study (e.g. Anti-allergy, glucocorticoid, aspirin, non- steroidal&#xD;
             anti-inflammatory, asthma or hay fever medication).&#xD;
&#xD;
          -  Known sensitivity to the test articles or their constituents including patch materials&#xD;
             (for example tape/plaster adhesive).&#xD;
&#xD;
          -  Current treatment by a physician for allergy unless physician consulted by&#xD;
             Investigator and participation approved.&#xD;
&#xD;
          -  Participation in a repeat insult patch test (RIPT) or follow-up work within the last&#xD;
             month.&#xD;
&#xD;
          -  Sensitisation or questionable sensitisation in a RIPT.&#xD;
&#xD;
          -  Recent immunisation (less than 10 days prior to test patch application).&#xD;
&#xD;
          -  A medical history indicating atopy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anurag Singh, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Amazentis SA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anurag Singh, MD, PhD</last_name>
    <phone>+41215521274</phone>
    <email>asingh@amazentis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PCR Corp, 667A Stockport Road</name>
      <address>
        <city>Manchester</city>
        <zip>M12 4QE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew King</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HRIPT</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

